A team of 70 Ambassadors and High Commissioners from several nations visited the Bharat Biotech facility at Genome Valley, Hyderabad today to learn more about their work to establish a safe and efficacious vaccine against COVID-19.
The delegation led by the Ministry of External Affairs comprised of High Commissioners and Government representatives of 70 countries across the world from Asia, Africa, Europe, North America, South America, and Oceania.
The delegation was briefed about Bharat Biotech’s vaccine development program by Dr. Krishna Ella, Chairman and Managing Director, spearheading the COVAXIN™ research, development, clinical trials and production teams.
The delegates were presented Bharat Biotech’s research process, manufacturing capabilities, expertise, given virtual and physical tours of the facilities.
The envoys voiced their appreciation of Bharat Biotech work of national and global public health significance, working very hard for several months to establish a long-lasting efficacious vaccine to combat the extraordinary COVID 19, pandemic.
COVAXIN™, India’s indigenous COVID-19 vaccine by Bharat Biotech is developed in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV). This indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety Level 3) bio-containment facility.
COVAXIN is conducting the largest efficacy trials in India involving 26,000 subject across cities
We hope that with safety & efficacy data, Covaxin will be available in the first quarter of next year to the categories & the first responders according to the plan that govt of India is embarking upon for phased vaccination: Suchitra Ella, Joint Managing Director, Bharat Biotech https://t.co/zJwdb7QU9r pic.twitter.com/IG3GjhuAve
— ANI (@ANI) December 9, 2020
COVAXIN™ is a highly purified and inactivated 2 dose SARS-CoV2 vaccine, manufactured in a vero cell manufacturing platform with an excellent safety track record of more than 300 million doses.
COVAXIN™ has been evaluated in approximately 1000 subjects in Phase I and Phase II clinical trials, with promising safety and immunogenicity results.
The Phase III human clinical trials of COVAXIN™ began in November, involving 26,000 volunteers across India. This is India’s first and only Phase III efficacy study for a COVID-19 vaccine, and the largest phase III efficacy trial ever conducted for any vaccine in India.
Speaking on the occasion, Ms. Suchitra Ella, Joint Managing Director of Bharat Biotech added, “The development and clinical evaluation of COVAXIN™ marks a significant milestone for novel vaccinology in India. COVAXIN™ has garnered interest from several countries worldwide for supplies and introduction. It is an honour to have with us today all the distinguished ambassadors of various countries. It makes us proud to note that the world is looking up to India in the common fight against this deadly pandemic.”
About Bharat Biotech
Bharat Biotech has established an excellent track record of innovation with more than 140 global patents, a wide product portfolio of more than 16 vaccines, 4 bio-therapeutics, registrations in more than 116 countries and WHO Pre-qualifications.
Located in Genome Valley, the hub for the global biotech industry, the company has built a world-class vaccine & bio-therapeutics, research & product development, Bio-Safety Level 3 manufacturing, and vaccine supply and distribution.
Having delivered more than 4 billion doses of vaccines worldwide, Bharat Biotech continues to lead innovation and has developed vaccines for influenza H1N1, Rotavirus, Japanese Encephalitis, Rabies, Chikungunya, Zika and the world’s first tetanus-toxoid conjugated vaccine for Typhoid.
The company is proficient in conducting extensive multi-centre clinical trials, having completed more than 75 trials enrolling more than ~ 700,000 participants globally. Our commitment to global social innovation programs and public-private partnerships resulted in the introduction of path-breaking WHO pre-qualified vaccines BIOPOLIO®, ROTAVAC® and Typbar TCV® combating Polio, Rotavirus and Typhoid infections respectively. Bharat Biotech has successfully partnered with NIV-ICMR having developed JENVAC®, a licensed Japanese Encephalitis vaccine.
The 2019 acquisition of Chiron Behring (CHIRORAB®), has positioned Bharat Biotech as the largest Rabies vaccine manufacturer in the world.
Media contact for Bharat Biotech
